Recent Updates
Recently added Catalysts

CEP-37247

Phase 1

Sciatica | Small molecule | Other |Teva Pharmaceutical Industries Limited|Last Updated: Jul 21, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment98
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01240876Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk HerniationPHASE1 COMPLETED 98Jan 1, 2011Apr 1, 2013Jul 21, 201624 United States, Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Occurrence of adverse events compared to placebo
throughout the 28-week double-blind treatment period
Mean change in the weekly average of daily average pain intensity (API) in the affected leg on the 11-Point Numerical Rating Scale (NRS-11)
at week 4 compared with baseline

The average pain intensity over the past 24 hours on the NRS-11 will be collected daily by electronic diary.

Secondary Endpoints
Weekly average of daily leg API score as assessed by the NRS-11 from electronic diary entries
at each of the first 6 weeks
Weekly average of daily back API score as assessed by the NRS-11 from electronic diary entries
at each of the first 6 weeks
Weekly average of daily worst leg pain score as assessed by the NRS-11 from electronic diary entries
at each of the first 6 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
CEP-37247EXPERIMENTAL -
Matching placeboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
CEP-37247DRUG0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
PlaceboDRUGMatching placebo vials will be filled with the buffered solution for CEP-37247.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites24

Inclusion Criteria: * Over the 4 days prior to the randomization visit, the patient has a mean score greater than or equal to 5 (of 10) for "Average Pain Over the Past 24 Hours" for the pain in the affected leg as assessed by the 11-Point Numerical Rating Scale (NRS-11) captured in the electronic d...

Countries:United StatesAustralia
Unlock Eligibility Criteria